Adjunctive effects of aripiprazole on metabolic profiles: Comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 40, Issue 1, 2013, Pages 260-266

  Wang, Liang Jen ^a,b   Ree, Shao Chun ^a   Huang, Yu Shu ^a,b   Hsiao, Cheng Cheng ^c   Chen, Chih Ken ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

Author keywords

Antipsychotics; Aripiprazole; Dyslipidemia; Metabolic syndrome; Schizophrenia

Indexed keywords

ADIPONECTIN; AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BIPOLAR DISORDER; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; LOADING DRUG DOSE; MALE; METABOLIC DISORDER; METABOLIC PARAMETERS; METABOLIC REGULATION; OPEN STUDY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; WEIGHT REDUCTION;

ADIPONECTIN; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; OBESITY; PIPERAZINES; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; QUINOLONES; WEIGHT GAIN;

EID: 84868582116     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.10.010     Document Type: Article

References (47)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, Text Revision, American Psychiatric Association, Washington DC. 4th ed.
2. Bai Y.M., Chen J.Y., Yang W.S., Chi Y.C., Liou Y.J., Lin C.C., et al. Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia. J Clin Psychiatry 2007, 68:1834-1839.
3. Bai Y.M., Chen T.T., Yang W.S., Chi Y.C., Lin C.C., Liou Y.J., et al. Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study. Schizophr Res 2009, 111:1-8.
4. Barnes T.R. The Barnes Akathisia Rating Scale-revisited. J Psychopharmacol 2003, 17:365-370.
5. Bickerdike M.J. 5-HT2C receptor agonists as potential drugs for the treatment of obesity. Curr Top Med Chem 2003, 3:885-897.
6. Boullart A.C., de Graaf J., Stalenhoef A.F. Serum triglycerides and risk of cardiovascular disease. Biochim Biophys Acta 2012, 1821:867-875.
7. Chang J.S., Ahn Y.M., Park H.J., Lee K.Y., Kim S.H., Kang U.G., et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008, 69:720-731.
8. Chang J.S., Lee N.Y., Ahn Y.M., Kim Y.S. The sustained effects of aripiprazole-augmented clozapine treatment on the psychotic symptoms and metabolic profiles of patients with refractory schizophrenia. J Clin Psychopharmacol 2012, 32:282-284.
9. Chen C.H., Huang M.C., Lu M.L. Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients. J Clin Psychopharmacol 2007, 27:516-517.
10. Choi K.M., Lee J., Lee K.W., Seo J.A., Oh J.H., Kim S.G., et al. The associations between plasma adiponectin, ghrelin levels and cardiovascular risk factors. Eur J Endocrinol 2004, 150:715-718.
11. De Risio A., Pancheri A., Simonetti G., Giannarelli D., Stefanutto L., Gentile B. Add-on of aripiprazole improves outcome in clozapine-resistant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:1112-1116.
12. Deng C., Chen J., Hu C., Huang X.F. What is the mechanism for aripiprazole's effect on reducing olanzapine-associated obesity?. J Clin Psychopharmacol 2010, 30:480-481.
13. Englisch S., Zink M. Combined antipsychotic treatment involving clozapine and aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1386-1392.
14. Fleischhacker W.W., Heikkinen M.E., Olie J.P., Landsberg W., Dewaele P., McQuade R.D., et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 2010, 13:1115-1125.
15. Hanssens L., van Winkel R., Wampers M., Van Eyck D., Scheen A., Reginster J.Y., et al. A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder. Schizophr Res 2008, 106:308-314.
16. Henderson D.C., Kunkel L., Nguyen D.D., Borba C.P., Daley T.B., Louie P.M., et al. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand 2006, 113:142-147.
17. Henderson D.C., Fan X., Copeland P.M., Sharma B., Borba C.P., Boxill R., et al. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol 2009, 29:165-169.
18. Jin H., Meyer J.M., Mudaliar S., Jeste D.V. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr Res 2008, 100:70-85.
19. Karunakaran K., Tungaraza T.E., Harborne G.C. Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?. J Psychopharmacol 2007, 21:453-456.
20. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
21. Kroeze W.K., Hufeisen S.J., Popadak B.A., Renock S.M., Steinberg S., Ernsberger P., et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003, 28:519-526.
22. Lane R.D., Glazer W.M., Hansen T.E., Berman W.H., Kramer S.I. Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale. J Nerv Ment Dis 1985, 173:353-357.
23. Lee S.Y., Park M.H., Patkar A.A., Pae C.U. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:490-496.
24. Lewis G.F., Carpentier A., Adeli K., Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002, 23:201-229.
25. Mukundan A., Faulkner G., Cohn T., Remington G. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev 2010, CD006629.
26. Naber D., Lambert M. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:1213-1219.
27. Nasrallah H.A. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008, 13:27-35.
28. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(Suppl. 1):1-93.
29. Newcomer J.W. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007, 68(Suppl. 1):20-27.
30. Newcomer J.W., Campos J.A., Marcus R.N., Breder C., Berman R.M., Kerselaers W., et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry 2008, 69:1046-1056.
31. Nonogaki K., Ohashi-Nozue K., Oka Y. A negative feedback system between brain serotonin systems and plasma active ghrelin levels in mice. Biochem Biophys Res Commun 2006, 341:703-707.
32. Osuntokun O., Millen B., Xu W.I., Kryzhanovskaya L.A., Robertson-Plouch C., Carlson J.L., et al. Metabolic parameters in patients treated with olanzapine or other atypical antipsychotics. J Psychopharmacol 2011, 25:630-638.
33. Pramyothin P., Khaodhiar L. Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes 2010, 17:460-466.
34. Rummel-Kluge C., Komossa K., Schwarz S., Hunger H., Schmid F., Lobos C.A., et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010, 123:225-233.
35. Rummel-Kluge C., Komossa K., Schwarz S., Hunger H., Schmid F., Kissling W., et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull 2012, 38:167-177.
36. Shapiro D.A., Renock S., Arrington E., Chiodo L.A., Liu L.X., Sibley D.R., et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003, 28:1400-1411.
37. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 59(Suppl. 20):22-33. [quiz 34-57].
38. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970, 212:11-19.
39. Spurling R.D., Lamberti J.S., Olsen D., Tu X., Tang W. Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review. J Clin Psychiatry 2007, 68:406-409.
40. Starrenburg F.C., Bogers J.P. How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins. Eur Psychiatry 2009, 24:164-170.
41. Stroup T.S., McEvoy J.P., Ring K.D., Hamer R.H., LaVange L.M., Swartz M.S., et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 2011, 168:947-956.
42. Takeuchi H., Uchida H., Suzuki T., Watanabe K., Kashima H. Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: one-year follow-up study. Psychiatry Clin Neurosci 2010, 64:104-106.
43. Tschoner A., Engl J., Rettenbacher M., Edlinger M., Kaser S., Tatarczyk T., et al. Effects of six second generation antipsychotics on body weight and metabolism - risk assessment and results from a prospective study. Pharmacopsychiatry 2009, 42:29-34.
44. Turner M.S., Stewart D.W. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses. J Psychopharmacol 2006, 20:20-37.
45. Wampers M., Hanssens L., van Winkel R., Heald A., Collette J., Peuskens J., et al. Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study. Eur Neuropsychopharmacol 2012, 22:17-26.
46. World Health Organization http://www.whocc.no/atc_ddd_index/.
47. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2000, 284:3043-3045.